McMaster PLUS Selected
This article has been identified as especially clinically relevant or newsworthy by at least 3
practicing clinicians and of high scientific quality by expert researchers
as a part of the McMaster PLUS article rating service.
DescriptorName: DiabetesMellitus, Type1... AbstractText: Hypoglycemia, common in patients with type1diabetes, is a major barrier to achieving good glycemic control... risk difference, -6.8%; 95% CI, -10.8% to -2.7%) AbstractText: Among patients with type1diabetes and at least 1 risk factor for hypoglycemia, 32 weeks' treatment with ...
Endocrine Disorders (4) Hypoglycemia (11), Diabetes Mellitus, Type 1 (4), Coma (1), more mentions
... 60-min C-peptide levels) as prediagnostic end points for type1diabetes among Type1Diabetes TrialNet Pathway to Prevention Study participants AbstractText: Two cohorts were ... In contrast, HRs of IND/DYS- and type1diabetes with age and 30-0-min C-peptide were consistent ... without Index60 ≥1.00 is a suboptimal prediagnostic end point for type1diabetes.
Endocrine Disorders (9) Diabetes Mellitus, Type 1 (9), more mentions
AbstractText: Although patients with type1diabetes have a poor prognosis after a stroke, predictors of survival ... study, a total of 144 patients of 4,083 with type1diabetes from the Finnish Diabetic Nephropathy (FinnDiane) Study suffered an incident stroke in 1997-2010 ... cause mortality increased with deteriorating kidney function AbstractText: Patients with type1diabetes with an incident stroke have a poor cardiovascular prognosis and ...
Endocrine Disorders (6), Kidney Disease (2) Diabetes Mellitus, Type 1 (4), Diabetic Nephropathies (2), Diabetes Mellitus (2), more mentions
AbstractText: The American Diabetes Association (ADA) annually updates Standards of Medical Care in Diabetes to provide clinicians, patients, researchers, payers, and other interested parties ... based recommendations for the diagnosis and management of patients with diabetes AbstractText: For the 2017 Standards of Care, the ADA Professional ... Care about monitoring and pharmacologic approaches to glycemic management for type1diabetes.
Endocrine Disorders (7) Diabetes Mellitus (5), Diabetes Mellitus, Type 1 (2), more mentions
... percutaneous coronary intervention (PCI) may offer a survival benefit in patients with type1diabetes (T1D) in need of multivessel revascularization AbstractText: This study sought to determine ... in Heart disease Evaluated According to Recommended Therapies) register, the Swedish National Diabetes Register, and the Swedish National Patient Register to retrieve information about patient ...
... exists on the relationship between HbA1c variability and mortality in Type1diabetes... variability and mortality exists in a population of people with Type1diabetes... onset of first hospital admission between groups AbstractText: People with Type1diabetes were identified for inclusion from the Scottish Care Information - Diabetes data set ...
Endocrine Disorders (8) Diabetes Mellitus, Type 1 (6), Diabetes Mellitus (2), more mentions
Background In most patients with type1diabetes, adequate glycemic control is not achieved with insulin therapy alone ... Conclusions Among patients with type1diabetes who were receiving insulin, the proportion of patients who achieved ... hemoglobin level lower than 7.0% with no severe hypoglycemia or diabetic ketoacidosis was larger in the group that received sotagliflozin than ...
Endocrine Disorders (7) Diabetes Mellitus, Type 1 (5), Diabetic Ketoacidosis (4), Hypoglycemia (4), more mentions
Context: Closed-loop control (CLC) for the management of T1D is a novel method for optimizing glucose control and strategies for individualized implementation are being developed.
Objective: Analyze glycemic control in an Overnight CLC system designed to "reset" the patient to near normal glycemic targets every morning.
Design: Randomized cross-over multicenter clinical trial.
Participants: 44 subjects with T1D on insulin pump therapy.
Intervention: Sensor-augmented pump therapy (SAP) at home vs 5 nights of CLC (active from 23:00 to 07:00) in a supervised outpatient setting (research house or hotel) with a substudy of 5 nights of CLC subsequently at home.
Main Outcome Measure: Percent time spent in target range (70-180 mg/dL measured by CGM).
Results: 40 subjects (age:45.5±9.5 years, HbA1c:7.4±0.8%) completed the study. Time in target range (70-180 mg/dL) significantly improved in CLC vs. SAP over 24 hours (78.3% vs. 71.4%, p=0.003) as well as overnight (85.7% vs. 67.6%, p<0.001). Time spent in a hypoglycemic range (<70 mg/dL) significantly decreased in CLC vs. SAP over 24 hours (2.5% vs. 4.3%, p=0.002) and overnight (0.9% vs. 3.2%, p<0.001). Mean glucose at 07:00 was lower with CLC vs. SAP (123.7 vs. 145.3 mg/dL, p<0.001). The substudy at home, involving 10 T1D subjects, showed similar trends with increased time in target (70-180 mg/dL) overnight (75.2% vs. 62.2%, p=0.07) and decreased time spent in hypoglycemic range (<70 mg/dL) overnight in CLC vs SAP (0.6% vs. 3.7%, p=0.03).
Conclusion: Overnight-only CLC increased time in target range over 24 hours and decreased time in hypoglycemic range over 24 hours in a supervised outpatient setting. A pilot extension study at home showed a similar non-significant trend.
Endocrine Disorders (2) Diabetes Mellitus, Type 1 (1), more mentions
... 6 (HHV6) A and B in human pancreata and to search for signs of active infection in this organ of subjects with and without type1diabetes (T1D).Pancreata from brain-dead organ donors with and without T1D were examined for the presence of HHV6 genomic sequences by polymerase chain reaction ...
Endocrine Disorders (2) Diabetes Mellitus, Type 1 (2), Infections (2), more mentions